X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pegvisomant (376) 376
humans (299) 299
acromegaly (270) 270
endocrinology & metabolism (261) 261
index medicus (230) 230
human growth hormone - analogs & derivatives (157) 157
acromegaly - drug therapy (154) 154
female (143) 143
male (139) 139
human growth hormone - therapeutic use (125) 125
adult (118) 118
somatostatin analogs (108) 108
middle aged (107) 107
growth hormone (101) 101
medicine & public health (87) 87
receptors, somatotropin - antagonists & inhibitors (84) 84
octreotide (82) 82
somatostatin - analogs & derivatives (79) 79
receptor antagonist pegvisomant (77) 77
diabetes (74) 74
growth-hormone (71) 71
somatotropin (69) 69
insulin-like growth factor i - metabolism (67) 67
aged (65) 65
igf-i (63) 63
therapy (62) 62
acromegaly - metabolism (58) 58
somatostatin - therapeutic use (57) 57
long-term treatment (56) 56
care and treatment (54) 54
animals (51) 51
efficacy (48) 48
long-term (48) 48
growth-factor-i (47) 47
endocrinology (46) 46
treatment outcome (46) 46
acromegaly - therapy (44) 44
cabergoline (44) 44
hormone-receptor antagonist (44) 44
somatostatin (44) 44
acromegaly - blood (43) 43
antagonist pegvisomant (41) 41
health aspects (41) 41
transsphenoidal surgery (41) 41
octreotide - therapeutic use (40) 40
follow-up (39) 39
lanreotide (39) 39
radiotherapy (38) 38
factor-i (37) 37
human growth hormone - adverse effects (36) 36
insulin-like growth factor i (36) 36
mortality (36) 36
human growth hormone - pharmacology (35) 35
research (35) 35
somatostatin analogues (35) 35
diagnosis (34) 34
dopamine agonists - therapeutic use (33) 33
young adult (33) 33
human growth hormone - blood (32) 32
internal medicine (32) 32
surgery (32) 32
retrospective studies (31) 31
acromegaly - surgery (30) 30
safety (30) 30
secreting pituitary-adenomas (30) 30
adenoma - drug therapy (29) 29
insulin (28) 28
insulin-like growth factor i - analysis (28) 28
acromegaly - diagnosis (27) 27
acromegaly - etiology (27) 27
adolescent (27) 27
hormone antagonists - therapeutic use (27) 27
human growth hormone - administration & dosage (27) 27
human physiology (27) 27
management (27) 27
physiological aspects (27) 27
pituitary-adenomas (27) 27
glucose (26) 26
glucose-tolerance (26) 26
pasireotide (26) 26
pharmacology & pharmacy (26) 26
pituitary (26) 26
human growth hormone - metabolism (25) 25
igf-1 (25) 25
pituitary neoplasms - drug therapy (25) 25
tumors (25) 25
clinical-practice (24) 24
drug therapy, combination (24) 24
growth-hormone-receptor (24) 24
quality-of-life (24) 24
somatostatin analog therapy (24) 24
abridged index medicus (23) 23
growth hormone receptor antagonist (23) 23
oncology (23) 23
pituitary adenoma (23) 23
acromegaly - complications (21) 21
analysis (21) 21
cell biology (21) 21
experience (21) 21
magnetic resonance imaging (21) 21
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (455) 455
Spanish (8) 8
German (6) 6
French (4) 4
Czech (1) 1
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
Russian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Endocrinology, ISSN 0022-0795, 2015, Volume 226, Issue 2, pp. T141 - T160
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 03/2019, Volume 104, Issue 3, pp. 915 - 924
Background: The response to first-generation somatostatin receptor ligands (SRLs) treatment in acromegaly correlates with expression of somatostatin receptor... 
OCTREOTIDE | RESISTANT | ANALOG SOM230 | PEGVISOMANT | GROWTH-HORMONE | I IGF-I | ENDOCRINOLOGY & METABOLISM | SECRETION | DISTINCT PATTERNS | ADENOMAS
Journal Article
Endocrinologia y Nutricion, ISSN 1575-0922, 10/2016, Volume 63, Issue 8, pp. 397 - 408
Purpose To describe real-world use of lanreotide combination therapy for acromegaly. Patients and methods ACROCOMB is a retrospective observational Spanish... 
IGF-I | Somatostatin analogues | Pegvisomant | Lanreotide | Acromegaly | Cabergoline
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 06/2019, Volume 104, Issue 6, pp. 1978 - 1988
Pasireotide long-acting release (LAR) is a somatostatin multi-receptor ligand and in the current consensus criteria pasireotide LAR is considered the... 
SOMATOSTATIN ANALOG SOM230 | IN-VITRO | PEGVISOMANT | LONG-ACTING OCTREOTIDE | SAFETY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | CLINICAL-PRACTICE | LANREOTIDE | PITUITARY-ADENOMAS | 120 MG
Journal Article
Medicina Clinica, ISSN 0025-7753, 11/2013, Volume 141, Issue 10, pp. 442 - 446
Background and objective: Carbohydrate metabolism (CHM) is impaired in over 50% of acromegalic patients. Natural history of acromegaly and treatment modalities... 
Somatostatin analogues | Pegvisomant | Complications | Acromegaly | Diabetes | Epidemiology
Journal Article
Growth Hormone & IGF Research, ISSN 1096-6374, 08/2013, Volume 23, Issue 4, pp. 114 - 119
The study was conducted to evaluate the pharmacokinetics (PK), relative bioavailability (relBA), safety and tolerability of two single-dose pegvisomant... 
Acromegaly | Relative bioavailability | Pegvisomant | Pharmacokinetics | Subcutaneous injection
Journal Article